SLC5A2 and kidney disorder: In addition, sodium-glucose cotransporter-2 (SGLT2) inhibitors are hypoglycemic agents that promote urinary glucose excretion and have been reported to reduce the development of nephropathy as well as cardiovascular disease in several large clinical trials9–11.